Drug Trial Radar · NCT04650399
A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents
Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
754
Actual
Start
Feb 14, 2022
Primary completion
Mar 14, 2023
Study completion Feb 16, 2024
Sponsor
- Lead sponsor
- Butantan InstituteGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Valneva Austria GmbH
- First posted
- Dec 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This was a prospective, randomized, double-blinded, multicenter, pivotal study evaluating the full dose of VLA1553 (1 x10E4 TCID50 per dose) in comparison to a placebo control. The dose of VLA1553 or control was administered as single vaccination on Day 1. Overall, approximately 750 male and female participants aged 12 years to \<18 years were enrolled into the study. After completion of the trial, a Post Trial Access program was performed to offer the VLA1553 vaccine to all placebo recipients.
Conditions
- Chikungunya
Interventions
ActiveBiological
Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate 1x10E4 TCID50 per dose (0.5 mL)
PlaceboBiological
Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo (0.5 mL)
Primary outcomes
What the sponsor says the trial is designed to measure.
- SeroprotectionTime frame: On study Day 29,which is 28 days after single vaccination
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Centro de Pesquisa Clínica da Faculdade de Medicina da Universidade Federal de Mato Grosso do Sul - UFMS
Campo Grande, Brazil
Centro de Estudos do Instituto de Infectologia Emílio Ribas
São Paulo, Brazil
CECOR - Centro Oncológico de Roraima
Boa Vista, Acre, Brazil
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Manaus, Amazonas, Brazil
Núcleo de Medicina Tropical - Universidade Federal do Ceará
Fortaleza, Ceará, Brazil
Associação Obras Sociais Irmã Dulce / Centro de Pesquisa Clínica - CPEC
Salvador, Estado de Bahia, Brazil
Centro de Pesquisa e Desenvolvimento de Fármacos (CPDF) - Universidade Federal de Minas Gerais, Instituto de Ciências Biológicas
Belo Horizonte, Minas Gerais, Brazil
Real Hospital Português de Beneficência em Pernambuco
Recife, Pernambuco, Brazil
Faculdade de Medicina de São José do Rio Preto - FAMERP
São José do Rio Preto, São Paulo, Brazil
Centro de Pesquisas Clínicas Universidade Federal Sergipe
Aracaju, Sergipe, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.